13 completed. 13 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 13 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow IgA Nephropathy: new trials by email Literature Review of IgA Nephropathy trials Research Report on IgA Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase IIa Study in Primary IgA Nephropathy Patients XH-S003 Capsule - IgA Nephropathy | Phase 2 | Completed | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 25 | 2024-12-31 | 2026-09-25 |
| Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy Atrasentan, Placebo - IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 2 | Completed | Novartis Pharmaceuticals | 54 | 2023-07-20 | 2026-07-20 |
| Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease ARO-C3, Placebo - C3 Glomerulopathy, IgA Nephropathy | Phase 1 / Phase 2 | Completed | Arrowhead Pharmaceuticals | 62 | 2022-02-01 | 2026-05-22 |
| A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. HR19042 Capsules, Placebo - IgA Nephropathy | Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 316 | 2021-09-09 | 2026-03-12 |
| Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) BION-1301 Single Dose, Placebo Single Dose, BION-1301 Multiple Doses - IgA Nephropathy | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 103 | 2019-04-08 | 2026-06-16 |
| Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies APL-2 - IgA Nephropathy, Lupus Nephritis | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 21 | 2018-02-26 | 2025-02-13 |
| Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation LNP023, Placebo - IgA Nephropathy | Phase 2 | Completed | Novartis Pharmaceuticals | 112 | 2018-02-07 | 2023-01-30 |
| A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX Bardoxolone methyl capsules - IgA Nephropathy, CKD Associated With Type 1 Diabetes | Phase 2 | Completed | Biogen | 103 | 2017-12-26 | 2025-06-03 |
| Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy Fostamatinib 150 mg, Fostamatinib 100 mg, Placebo - IGA Nephropathy | Phase 2 | Completed | Rigel Pharmaceuticals | 76 | 2014-10-01 | 2019-06-27 |
| BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration Blisibimod, Placebo - IgA Nephropathy | Phase 2 / Phase 3 | Completed | Anthera Pharmaceuticals | 57 | 2013-06-01 | 2017-09-18 |
| A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients Tacrolimus, Placebo - IgA Nephropathy | Phase 2 | Completed | Astellas Pharma Inc | 40 | 2010-11-01 | 2014-08-21 |
| Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy ACE inhibitor + statin, Sirolimus (study drug)+ACE inhibitor + statin - Glomerulonephritis, IGA, Nephropathy, IGA | Phase 2 | Completed | Josep m Cruzado | 23 | 2006-01-01 | 2011-09-16 |
| Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study Budesonide - IGA Nephropathy | Phase 2 | Completed | Calliditas Therapeutics AB | 20 | 2005-10-01 | 2009-04-21 |
Glomerulonephritis, IGA (13) · Kidney Diseases (2) · Renal Insufficiency, Chronic (2) · Glomerulonephritis (1) · Glomerulonephritis, Membranoproliferative (1) · Glomerulonephritis, Membranous (1) · Glomerulosclerosis, Focal Segmental (1) · Lupus Nephritis (1) · Polycystic Kidney, Autosomal Dominant (1) · Urologic Diseases (1)
Autoimmune Diseases (13) · Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Immune System Diseases (13) · Male Urogenital Diseases (13) · Nephritis (13) · Urogenital Diseases (13) · Glomerulonephritis (12) · Urologic Diseases (12) · Kidney Diseases (11) · Chronic Disease (2) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Renal Insufficiency (2)
AMG623 peptibody (1) · Angiotensin-Converting Enzyme Inhibitors (1) · Anti-Inflammatory Agents (1) · Atrasentan (1) · Budesonide (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Sirolimus (1) · Tacrolimus (1) · bardoxolone methyl (1) · fostamatinib (1)
Novartis Pharmaceuticals (3) · Anthera Pharmaceuticals (1) · Apellis Pharmaceuticals, Inc. (1) · Arrowhead Pharmaceuticals (1) · Astellas Pharma Inc (1) · Biogen (1) · Calliditas Therapeutics AB (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Josep m Cruzado (1) · Rigel Pharmaceuticals (1) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1)
South Korea (6) · United Kingdom (5) · United States (5) · Germany (4) · Australia (3) · China (3) · Hong Kong (3) · Malaysia (3) · Taiwan (3) · Thailand (3) · Brazil (2) · Czechia (2) · Singapore (2) · Spain (2) · Sweden (2)
Josep M Cruzado, Medical Doctor (1) · Meritxell Ibernon, MD (1)
PMID 38299639, PMID 26032537, PMID 23977072, PMID 30177021, PMID 34124781, PMID 37036696, PMID 40482854, PMID 41904616
2023 (2), 2005 (1), 2014 (1), 2017 (1), 2018 (1)